Compare Eli Lilly And Co (LLY) vs iShares Silver Trust (SLV) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

SLV, the iShares Silver Trust ETF, trades at $50.98 with a slight 0.39% daily gain. The technical outlook is bearish, with moving averages signaling strong selling pressure and oscillators neutral. Recent news highlights silver's dual role as a monetary and industrial metal, with supply deficits and geopolitical tensions influencing prices. Financial ratios are not applicable as SLV is a commodity trust tracking silver prices, not a company with earnings.

The outlook for SLV hinges on silver's price trajectory, supported by industrial demand and supply constraints but pressured by Fed policy and dollar strength. Risks include volatility from macroeconomic shifts and competition from other silver ETFs like SIVR. Analyst sentiment is mixed, with silver's performance lagging gold year-to-date, yet long-term demand drivers remain intact.